Resignations over the beni-koji supplement harm, and the governance reset (2024)
A change of governance forced by trust, not efficiency
What makes this decision unusual is that it was not a strategy about growth or efficiency: a failure of quality and of disclosure, bearing on consumers’ lives, was what brought roughly 140 years of founding-family management to a close. Holding niche markets with distinctive products, and having every employee submit ideas each month — that “Kobayashi-ness” had been the strength underpinning the company’s high margins. The same corporate character can be seen as the obverse, in governance and quality control, of concentration on the founding family and weak external discipline. It was an episode in which the weakness on the underside of the strength was exposed in the worst possible form.
Replacing the management in acceptance of responsibility, and bringing in an outside chairman, was a decisive move to change who holds governance. Yet the structure has not changed: the founding family holds about 30% of the shares, and the two principals remain inside the company. With activist shareholders pressing that this is “insufficient,” how far an outside perspective can be converted into real discipline is the task left to this company. What a firm that has relied on the centripetal force of its founding family puts at the core of its governance once it lets that force go — the question the beni-koji affair posed remains open even after the crisis has passed.
Revenue and net margin, FY2019–FY2025
Revenue in ¥ bn (bars) and net margin in % (line), for the years around the decision. Shaded columns are FY2024 onwards — after it was taken.
Source: securities reports
Read the full dossier in Japanese →
The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.
Other key decisions at Kobayashi Pharmaceutical
Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →
Disclaimer
- This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
- Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
- Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
- Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
- Company names, logos and other marks belong to their respective owners.
Data API
Kobayashi Pharmaceutical’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
| Method | Endpoint | Returns |
|---|---|---|
| GET | /api/companies.json | All companies |
| GET | /api/4967/manifest.json | Resource index |
| GET | /api/4967/history.json | History overview |
| GET | /api/4967/timeline.json | Chronology |
| GET | /api/decisions.json | All management decisions (index) |
| GET | /api/4967/decisions.json | Management decisions (index) |
| GET | /api/4967/decisions/{slug}.json | One decision (full dossier) |
| GET | /api/4967/executives.json | Executives |
| GET | /api/4967/shareholders.json | Major shareholders |
| GET | /api/4967/financials.json | Financial statements |
| GET | /api/4967/financials-longterm.json | Long-term results |
| GET | /api/4967/segments.json | Business segments |
| GET | /api/4967/regions.json | Sales by region |
| GET | /api/4967/workforce.json | Workforce |